ProMetic Life Sciences Inc.

TSX: PLI

MONTREAL, QUEBEC--(Marketwire - Oct. 23, 2009) - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") announced today that it has been selected by the American Society of Nephrology for multiple presentations regarding PBI-1402 at its 42nd Annual Meeting & Scientific Exposition, being held from October 27 to November 1, 2009, in San Diego, California.

ProMetic's orally active lead compound for the treatment of anemia, PBI-1402, is in clinical development for the treatment of anemia induced by chemotherapy ("CIA") and/or related to cancer ("CRA"). A Phase Ib/II clinical trial demonstrated significant increases in hemoglobin and red blood cells as well as a reduction of the need for blood transfusion in patients with CIA.

PBI-1402's therapeutic activity has been further tested in well established animal models designed to simulate different renal diseases in humans. The presentations will be highlighting some of these significant preclinical results.

Dr. Lyne Gagnon, ProMetic's Director of Research and Development, Biology, and other investigators, will be presenting data during three poster sessions at the following times:

- Thursday, October 29, 2009 from 10:00 - 12:00 (PST) - Poster Session TH-PO102 - Oral treatment with PBI-1402 improves glomerular filtration rate by reducing tubulo-interstitial fibrosis and sclerosis in 5/6 nephrectomized (NX) rats;

- Saturday, October 31, 2009 from 10:00 - 12:00 (PST) - Poster Session SA-PO2200 - Oral treatment of PBI-1402 prevents doxorubicin-induced nephrotoxicity in mice;

- Saturday, October 31, 2009 from 10:00 - 12:00 (PST) - Poster Session SA-PO2424 - Oral treatment with PBI-1402 increases hemoglobin, hematocrit and red blood cell formation in 5/6 nephrectomized (NX) rats, a model mimicking human end-stage renal disease (ESRD).

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. (www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic LigandTM technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematological diseases and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and business development activities in the U.S., Europe, Asia and in the Middle-East.